ArticleAntimicrobial agents and chemotherapy2019
Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 48 citations in OpenAlex.
- Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review.Infection · 2026Review
- Intravenous fosfomycin-containing regimens are associated with reduced acute kidney injury in carbapenem-resistant Gram-negative infections: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- In Vitro Evaluation of Fosfomycin Combinations Against Metallo-β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Expression and characterization of the new antimicrobial peptide AP138L-arg26 anti Staphylococcus aureus.Applied microbiology and biotechnology · 2024Article
- Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations?Infectious diseases and therapy · 2024Review
- Enhancing Gentamicin Antibacterial Activity by Co-Encapsulation with Thymoquinone in Liposomal Formulation.Pharmaceutics · 2024Article
- Synergism with Shikimic Acid Restores β-Lactam Antibiotic Activity against Methicillin-ResistantMolecules (Basel, Switzerland) · 2024Article
- High-Yield Preparation of American Oyster Defensin (AOD) via a Small and Acidic Fusion Tag and Its Functional Characterization.Marine drugs · 2023Article
- In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae.Scientific reports · 2023Article
- Site Mutation Improves the Expression and Antimicrobial Properties of Fungal Defense.Antibiotics (Basel, Switzerland) · 2023Article
- Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19.International journal of antimicrobial agents · 2023Observational
- Prediction and bioactivity of small-molecule antimicrobial peptides fromFrontiers in microbiology · 2023Article
- Exogenous glutathione reverses meropenem resistance in carbapenem-resistantFrontiers in pharmacology · 2023Article
- Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study.Infection and drug resistance · 2023Article
- Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations.Antibiotics (Basel, Switzerland) · 2022Article
- Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations.Infectious disease reports · 2022Review
- In Vitro Pharmacodynamics and Bactericidal Mechanism of Fungal Defensin-Derived Peptides NZX and P2 againstMicroorganisms · 2022Article
- Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Fosfomycin and nitrofurantoin: classic antibiotics and perspectives.The Journal of antibiotics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of combining fosfomycin with various antimicrobial agents were evaluated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.